Emerging roles for cyclooxygenase-2 in gastrointestinal mucosal defense

Wallace, John L; Devchand, Pallavi R

doi:10.1038/sj.bjp.0706201

Javascript is disabled or not supported in your browser. JavaScript must be enabled in order for you to use WIKINDX fully. Enable JavaScript through your browser options then try again, otherwise, try using a different browser.

BioAcyl Corp

WIKINDX Resources

Wallace, J. L., & Devchand, P. R. (2005). Emerging roles for cyclooxygenase-2 in gastrointestinal mucosal defense. British Journal of Pharmacology, 145(3), 275–282.
Added by: Dr. Enrique Feoli (03/04/2022, 17:30) Last edited by: Dr. Enrique Feoli (03/04/2022, 17:31)

Resource type: Journal Article
DOI: 10.1038/sj.bjp.0706201
ID no. (ISBN etc.): 0007-1188
BibTeX citation key: Wallace2005
View all bibliographic details

Categories: BioAcyl Corp
Subcategories: Chronic NSAIDS
Creators: Devchand, Wallace
Collection: British Journal of Pharmacology

Views: 5/356

Abstract

The development of selective inhibitors of cyclooxygenase-2 (COX-2) was based on the concept that this enzyme played little, if any, role in modulating the ability of the gastrointestinal (GI) tract to resist and respond to injury. There is now overwhelming evidence that this is far from true. Indeed, COX-2 mediates several of the most important components of ‘mucosal defense', contributes significantly to the resolution of GI inflammation and plays a crucial role in regulating ulcer healing. COX-2 also contributes to long-term changes in GI function after bouts of inflammation.